

## A Top-Down/Bottom-Up Study of the Ribosomal Proteins of *Caulobacter crescentus*

William E. Running, Shobha Ravipaty, Jonathan A. Karty, and James P. Reilly\*

Department of Chemistry, Indiana University, Bloomington, Indiana 47405

Received June 23, 2006

Ribosomes from the Gram-negative  $\alpha$ -proteobacterium *Caulobacter crescentus* were isolated using standard methods. Proteins were separated using a two-dimensional liquid chromatographic system that allowed the analysis of whole proteins by direct coupling to an ESI-QTOF mass spectrometer and of proteolytic digests by a number of mass spectrometric methods. The masses of 53 of 54 ribosomal proteins were directly measured. Protein identifications and proposed post-translational modifications were supported by proteolysis with trypsin, endoprotease Glu-C, and exoproteases carboxypeptidases Y and P. Tryptic peptide mass maps show an average sequence coverage of 62%, and carboxypeptidase C-terminal sequence tagging provided unambiguous identification of the small, highly basic proteins of the large subunit. *C. crescentus* presents some post-translational modifications that are similar to those of *Escherichia coli* (e.g., N-terminal acetylation of S9 and S18) along with some unique variations, such as a near absence of L7 and extensive modification of L11. The comprehensive description of this organism's ribosomal proteome provides a foundation for the study of ribosome structure, dependence of post-translational modifications on growth conditions, and the evolution of subcellular organelles.

**Keywords:** ribosomal proteins • protein mass spectrometry • two-dimensional liquid chromatography • post-translational modifications

### Introduction

Ribosomes are enormous macromolecular complexes composed of ribonucleic acids (rRNAs) and proteins. In bacteria, their components include 3 rRNAs and some 54 proteins depending on the bacterial species. The average eubacterial ribosome has a molecular weight of 2.3 MDa, split unevenly between small (30S, 0.85 MDa) and large (50S, 1.45 MDa) subunits.<sup>1</sup> Because of their abundance, straightforward isolation, and variety (both in terms of sequence and size), ribosomal proteins are a commonly used model for the development of high capacity separations of biological samples.<sup>2–10</sup> The publication of crystal structures of the large and small subunits from Archaea and Eubacteria and of whole ribosomes from Eubacteria has sparked a renaissance in ribosome research.<sup>11–16</sup> Ribosomal proteins stabilize rRNA structure, enhance its inherent catalytic function, and provide sites for the interaction of the ribosome with other intracellular complexes to integrate translation with other cellular processes.<sup>17,18</sup> The evolution of proteins to enhance the stability, accuracy, and efficiency of an originally RNA-based translation system marks the emergence of definite ancestral lines, leading to modern cellular life.<sup>19,20</sup> Ribosomal proteins are studied in an attempt to understand the apparatus that evolved to integrate a crucial remnant of the prebiotic RNA World into modern protein-based metabolism.

Prokaryotic ribosomes are one of the most productively exploited targets for antibiotics, and new classes of ribosomal

antibiotics continue to be developed.<sup>21–23</sup> The inescapable linkage between the application of new antibiotics and the development of transferable resistance to those drugs justifies the development of techniques for inventory and characterization of the translational machinery from organisms other than just a few standard laboratory strains.<sup>24</sup>

We have used a combination of top-down and bottom-up approaches to characterize the ribosomal proteins of *Caulobacter crescentus*, a bacterium that is the subject of ongoing study in our laboratory.<sup>25–27</sup> This Gram-negative  $\alpha$ -proteobacterium's ribosomal proteins were selected to validate the effectiveness of a serial multistep two-dimensional liquid chromatography (2D-LC) apparatus (described in a companion publication by Karty<sup>28</sup>) rather than the exhaustively studied  $\gamma$ -proteobacterium *Escherichia coli*, because it is a member of a phylogenetic group containing the intracellular parasite *Rickettsia prowazekii* and the ancestor of the eukaryotic mitochondrion.<sup>29</sup> Identifications based on whole protein mass measurements were confirmed by mass spectrometric analysis of tryptic peptides (MS and MS/MS) and a mass spectrometry-based C-terminal sequencing approach using carboxypeptidases Y and P (CPY and CPP).<sup>30–34</sup>

### Materials and Methods

**Chemicals and Solvents.** Acetonitrile, glacial acetic acid, and urea were purchased from EMD Chemicals (Gibbstown, NJ). Water was purified using a Barnstead/Thermolyne E-Pure system (Barnstead/Thermolyne, Dubuque, IA). Type II bovine

\* Author for correspondence. E-mail: reilly@indiana.edu.

trypsin (T-8802), sequencing grade alkylated porcine trypsin (T-6567), magnesium acetate tetrahydrate, and Trizma base were obtained from the Sigma Chemical Co. (St. Louis, MO). Ammonium chloride, 2-mercaptoethanol, and 40% aqueous methylamine were supplied by Aldrich (Aldrich Chemical, Milwaukee, WI). Endoproteinase Glu-C (New England Biolabs, Beverly, MA), Carboxypeptidase Y (CPY) (Worthington Biochemicals, Lakewood, NJ), and Carboxypeptidase P (CPP) (Takara Mirus Bio, Madison, WI) were used for sequencing experiments.

**Bacterial Strains and Growth Conditions.** Starter cultures of *C. crescentus* CB15N were produced by overnight growth of cells from a single colony. The resulting culture was aliquoted into 5 mL starters with 10% by volume dimethyl sulfoxide (DMSO) as a cryopreservative and frozen at  $-80^{\circ}\text{C}$  until required. Cultures grown for the preparation of ribosomes were started by the inoculation of one starter culture into 500 mL of 2% peptone/1% yeast extract broth (PYE) (Difco/BD Biosciences, San Jose, CA) and grown for 12–14 h at  $30^{\circ}\text{C}$ , shaking at 150 rpm for aeration.

**Protein Sequence Data.** The most recently updated version of the *C. crescentus* proteome was obtained from The Institute for Genome Research ([www.tigr.org](http://www.tigr.org), Genbank Accession Number AE005673.1).<sup>35</sup> Theoretical molecular weights were calculated from this database using an in-house computer program, PRODIGIES.<sup>25</sup> Additional information on *C. crescentus* ribosomal protein sequences was obtained from the Swiss-Prot database at ExPASy ([www.expasy.org](http://www.expasy.org)).<sup>36</sup> When entries from Swiss-Prot are used, for example, for homology comparisons, accession numbers for the sequences are given. Homologies were assessed using the blast2p version of BLAST from the National Center for Biotechnology Information. ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).<sup>37</sup>

**Ribosome Preparation.** Ribosomes were prepared using Reilly and Arnold's modification of the method of Spedding.<sup>5,38</sup> The Buffers A, B, and E are those described by Spedding. Briefly, *C. crescentus* CB15N cells grown as described above were harvested by centrifugation at 6000g for 20 min, washed once with 250 mL of Buffer A per pellet, and then resuspended in a minimal volume of Buffer A plus miniComplete EDTA-free Protease Inhibitor Cocktail (1 tablet/10 mL of buffer, Roche Applied Science, Indianapolis, IN). Cells were lysed by 5 passes through a French press (Thermo Electron, Needham Heights, MA) at 16 000 psi, and the resulting lysate was cleared of cell debris by centrifugation at 30 000g for 45 min. Ribosomes were salt-washed twice at 100 000g for 16 h with an equal volume of 1.1 M sucrose in Buffer B. The final pellet was resuspended in Buffer E, dialyzed for 16 h against two 3000-fold vol excesses of that buffer to remove residual sucrose, and aliquoted into 100  $\mu\text{L}$  portions for storage at  $-80^{\circ}\text{C}$ . A typical preparation produced  $\sim 4$  mL of ribosome suspension with a protein concentration of 8 mg/mL by Bradford assay using bovine serum albumin as the standard.<sup>39</sup> When acid-extracted, the supernatant showed a protein concentration of 2.5 mg/mL, indicating minimal loss of protein from the sample.<sup>40</sup>

**Coupled 2D-LC-ESI-MS.** The 60 column chromatography device used in these experiments has been described in more detail elsewhere.<sup>28</sup> It consists of a strong cation exchange column feeding an array of 60 C4 reversed-phase "trap" columns, followed by 2 C4 reversed-phase "analysis columns". Because of the limited complexity of this protein mixture, only 20 of the traps were used in the experiments described below. Fluid handling and method control are supplied by two Waters

Alliance chromatographs (Waters, Milford, MA). Gradient methods provide the initial contact closure impulses that initiate control of the valve system by LabView version 6.1 (National Instruments, Austin, TX). All of the results reported below were obtained by injecting 50  $\mu\text{L}$  of an acetic acid/MgCl<sub>2</sub> extract containing 125  $\mu\text{g}$  of total protein, or 145 pmol of each protein.

**Dimension 1: Ion Exchange Chromatography.** Ion exchange separations were performed using a Waters Alliance 2695 Separations Module for solvent delivery and method control. A Toso-Haas SP-NPR column (4.6 mm  $\times$  35 mm, Tosoh Bioscience, Montgomeryville, PA) was developed using the mobile phases and gradient shown in Supplemental Table 1 of Supporting Information. Following a 10 min load time (during which any nonretained proteins were directed through Trap 1) and a 10 min wash (during which time IEC column effluent was directed through Trap 2), traps were switched every 5 min up to 100 min, at which time Trap 20 collected any tailing proteins.

**Dimension 2: Reversed Phase Chromatography.** Proteins eluting from the ion exchange dimension were trapped by ThermoHypersil Keystone Javelin guard columns (1.0 mm  $\times$  20 mm), packed with BioBasic C4 stationary phase. Analytical columns were ThermoHypersil Keystone Pioneer columns (1.0 mm  $\times$  100 mm), packed with the same material. Following development of the IEC dimension, trapping columns were washed for 2 min at 50  $\mu\text{L}/\text{min}$  with RPLC Buffer A (95% water, 5% acetonitrile, and 0.1% formic acid by volume). Buffer B and the gradient used are listed in Supplemental Table 2 of Supporting Information. A longer, flatter gradient with the alternate mobile phases, shown in Supplemental Table 3 of Supporting Information, was also used for some experiments.

**Dimension 3: Whole Protein Mass Spectrometry.** Whole protein mass spectra were acquired using a Micromass Q-ToF micro quadrupole time-of-flight mass spectrometer outfitted with an ESI ionization source. Reverse-phase column effluent was split from a flow rate of 50 to 7  $\mu\text{L}/\text{min}$  and directed to the ionization source.

Whole protein masses were determined by the manual selection of peaks in TICs from the reversed-phase chromatograms or with AutoME 1.1, a program that automates the spectral extraction and deconvolution process. When data were analyzed manually, spectra corresponding to a given chromatographic peak were summed together producing a sample spectrum that contained signals from all the charge states of the proteins present. Whole protein masses were extracted from these spectra by deconvolution using MaxEnt 1.

**Identification and Characterization of Ribosomal Proteins.** Few of the measured masses exactly matched calculated masses, and the discrepancies were accounted for by proposing various post-translational modifications. Enzymatic digestion methods were applied to confirm protein identities and modifications, and sometimes allowed the site of modification to be determined.

**Whole Protein C-Terminal Sequence Analysis with Carboxypeptidases Y and P.** Protein fractions collected from the 2DLC system were dried in a SpeedVac vacuum centrifuge (Jouan/Thermo Electron) and stored at  $-20^{\circ}\text{C}$  until needed. Prior to carboxypeptidase treatment, these fractions were resuspended in 30  $\mu\text{L}$  of 100 mM pyridine acetate buffer (pH 5.5), mixed with 50  $\mu\text{L}$  of saturated urea solution ( $\sim 12$  M), and incubated at  $37^{\circ}\text{C}$  for 15 min to denature the proteins. Twenty microliters of a solution containing 0.60  $\mu\text{g}$  of CPY and CPP or

1.20  $\mu\text{g}$  of CPY and CPP enzymes in pyridine acetate was then added to the denatured proteins. Digestions were performed at room temperature or at 37 °C. Aliquots were removed at several time points and acidified with 2% formic acid solution to quench the reaction. LC–MS analyses of the carboxypeptidase digests were performed using a Waters Alliance 2795 separations module coupled with a Q-ToF Micro mass spectrometer. Chromatographic separations were conducted on a BioBasic Pioneer C4 column (1 mm i.d.  $\times$  50 mm length) using conditions listed in Supplemental Table 4 of Supporting Information. The 50  $\mu\text{L}/\text{min}$  flow rate through the column was split to 10  $\mu\text{L}/\text{min}$  and directed to the electrospray ionization source.

Larger quantities of ribosomal proteins L11 and S21 were isolated for CPY/CPD digest analysis on an analytical-sized reverse-phase column (Jupiter C4, 4.6 mm i.d.  $\times$  250 mm length, 5  $\mu\text{m}$  particle size, Phenomenex, Torrance, CA). For these separations, conditions shown in Supplemental Table 5 of Supporting Information were used. A Waters 484 UV/vis detector was used in-line between the column and fraction collector to detect eluting proteins by their absorbance at 215 nm.

**Tryptic Digestion of Trapping Column Fractions.** Fractions collected from the analytical columns were taken to dryness to remove formic acid and resuspended in 10 mM ammonium bicarbonate buffer, after which 0.2  $\mu\text{g}$  of sequencing grade trypsin and 0.1  $\mu\text{g}$  of Type II bovine trypsin in 10 mM ammonium bicarbonate were added, giving a final volume of  $\sim$ 20  $\mu\text{L}$ . Samples were incubated for 12–16 h at 37 °C.

**Glu-C Digestion.** Peptide mass mapping using Glu-C digestion was employed to confirm the identity of ribosomal protein S21. The protein isolated by reversed-phase LC fractionation was dried and stored at  $-20$  °C. Prior to digestion, the protein was resuspended in 100 mM ammonium bicarbonate buffer. Thirty microliters of this solution was digested with 0.09  $\mu\text{g}$  of Glu-C by incubating at 37 °C for 14 h. The reaction was terminated by drying the sample. Glu-C digests were analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS).

**Capillary LC–ESI–MS/MS.** Peptide analysis by capillary LC–MS was performed using a ThermoElectron LCQ Deca XP Plus ion trap mass spectrometer and Surveyor chromatography system. Peptides ( $\sim$ 30 pmol total) were separated on 10 cm  $\times$  254  $\mu\text{m}$  i.d. capillary LC columns containing ThermoHypersil Keystone BioBasic C18. The 100  $\mu\text{L}/\text{min}$  flow rate from the HPLC pump was split 1:20 prior to the sample loop to give a flow rate of 5  $\mu\text{L}/\text{min}$  through the column. The separation gradient using 0.1% formic acid in water as Buffer A and 0.1% formic acid in acetonitrile as Buffer B is shown in Supplemental Table 6 of Supporting Information.

Combined MS and MS/MS spectra were searched against the most recent version of the *C. crescentus* CB15 proteome using TurboSEQUENT.<sup>40,41</sup> Because the expected set of proteins was small, TurboSEQUENT search results were all examined directly, with no filtering. Identifications that featured fewer than 3 matches, low quality MS/MS spectra (i.e., high noise levels, low intensities of fragment ions, short series of b- or y-ions),  $X_{\text{corr}}$  values less than 2.0 (regardless of proposed charge state), or that belonged to a protein that had not been identified in the trap during whole protein experiments were ignored.

**MALDI MS.** Tryptic digests were quenched and split for preparation of unguanidinated MALDI spectra or guanidination following the procedure of Beardsley and Reilly.<sup>42</sup> Both the

guanidinated and unguanidinated samples were concentrated by the use of homemade C18-loaded pipet tips and eluted with a matrix solution of 10 mg/mL  $\alpha$ -cyano-4-hydroxycinnamic acid in 50% water, 50% acetonitrile, and 0.5% TFA. A 1  $\mu\text{L}$  portion of this eluate was spotted for analysis with an ABI 4700 Proteome Analyzer (Applied Biosystems, Foster City, CA). Spectra were calibrated using external standard mixtures.

Mass spectra from pairs of spots representing unguanidinated and guanidinated aliquots of peptides from the same tryptic digest reaction were used to produce pairs of peak lists for analysis using the two-file comparison function of PRODIGIES.<sup>25</sup> Searches were performed against the latest version of the complete *C. crescentus* proteome. MASCOT searches were performed as “MS + MS – MS Combined” searches against the most recent version of the *C. crescentus* proteome database.<sup>43</sup> As with the capillary LC–MS data, the candidate list was small enough that the spectra supporting a particular identification could be examined directly. Identifications supported by MOWSE scores less than twice the threshold value (49 for the *C. crescentus* whole proteome), few MS/MS spectra, or low-intensity MS/MS spectra were rejected.

## Results

On the basis of earlier research in our laboratory with *E. coli*, we expected that the *C. crescentus* ribosomal protein preparation would contain all ribosomal proteins except S1 and contain a limited number of post-translational modifications.<sup>38,45</sup> The most common modification is removal of the N-terminal methionyl residue by N-terminal methionine aminopeptidase, a metalloendopeptidase that specifically removes methionine residues succeeded by amino acids with small side chains (G, A, S, T, P, and V).<sup>46,47</sup> After this modification, acetylation or methylation of amino groups occur most frequently. A few more exotic modifications were also anticipated, for example, the  $\beta$ -thiomethylation of an aspartyl residue in *E. coli* S12.<sup>48</sup> Each of these modifications results in a predictable change to the theoretical mass of a protein allowing a list of possible whole protein masses to be generated from the proteome. Provisional identifications for each component in the acid extract of a ribosome sample are then obtained by matching experimental whole protein masses to these calculated values. Variations on this straightforward strategy have been contemporaneously developed and applied to the characterization of the ribosomal proteomes of the  $\alpha$ -proteobacterium *Rhodospseudomonas palustris* and a strain of *Thermus thermophilus*, for which no genome sequence exists.<sup>9,10</sup>

The masses obtained for *C. crescentus* ribosomal proteins are listed in Table 1, along with theoretical masses calculated from the proteome and data on the elution position and sequence coverage for each protein. Of the 53 unique polypeptides in *C. crescentus* ribosomes, one-quarter were identified by direct matches with the theoretical masses. A further half of the ribosomal proteins were identified by subtracting the residue mass of methionine from the theoretical mass. The remaining one-quarter of the ribosomal proteins were identified by applying combinations of methionine removal ( $-131.2$  Da, “-Met”), acetylation ( $+42.04$  Da, “+CH<sub>3</sub>CO”), methylation ( $+14.03$  Da, “+CH<sub>2</sub>”), and, in one case, oxidation ( $+16$  Da, “+O”). This procedure produced matches for all but four ribosomal proteins: L3, L21, S1, and S21. L3, L21, and S21 were assumed to be the subjects of more exotic post-translational modifications. S1 is a component of actively translating polyribosomes but is often lost from tight-coupled ribosome prepa-

**Table 1.** Whole Protein and Digest Data for Ribosomal Proteins from *C. crescentus*

protein	theo. mass <sup>a</sup>	avg. mass	modifications	whole proteins location <sup>b</sup>	CapLC/ESI-MS % sequence	MALDI % sequence	net coverage % sequence
Ribosomal Large Subunit Proteins							
L1	23735.3	23618.8	-Met, +CH <sub>2</sub>	Trap 7	63	72	79
L2	30156.8	30028.7	-Met;	Trap 18	43	53	56
L3	28079.9	26666.7	Removal of residues 1-13	Trap 11	51	43	57
L4	22792.4	22794.9		Trap 16	31	52	60
L5	20965.5	20836.2	-Met	Trap 8	53	50	64
L6	18885.1	18756.1	-Met	Trap 13	44	41	51
L7/L12	13289.2	13172.9	-Met, +CH <sub>2</sub>	Trap 4	43	51	56
L9	20909.3	20910.2		Trap 6	32	47	47
L10	18039.0	18040.4		Trap 7	48	63	63
L11	15387.0	15509.5	-Met, 6 + 42 Da modifications	Trap 7	41	50	59
L13	17741.5	17743.5		Trap 11	45	40	54
L14	13369.8	13371.2		Trap 10	49	57	62
L15	16924.7	16795.8	-Met	Trap 12	67	50	73
L16	15851.6	15883.8	+CH <sub>2</sub> , +O	Trap 16	43	39	50
L17	15325.7	15327.6		Trap 18	70	70	75
L18	12443.2	12327.4	-Met, +CH <sub>2</sub>	Trap 11	58	48	63
L19	14521.7	14391.9	-Met	Trap 10	37	58	58
L20	13152.4	13023.0	-Met	Trap 19	33	53	58
L21	17857.6	17858.5		Trap 14	28	23	32
L22	14239.5	14109.8	-Met	Trap 12	49	41	65
L23	10715.5	10585.1	-Met	Trap 9	49	74	75
L24	10994.8	10864.8	-Met	Trap 9	57	65	74
L25	21232.3	21102.2	-Met	Trap 7	80	52	87
L27	9370.7	9111.2	-Met, -C-terminal glutamate.	Trap 12	32	41	43
L28	10630.4	10499.4	-Met	Trap 10	43	60	66
L29	7134.4	7135.0		Trap 7	59	59	59
L30	6811.9	6681.3	-Met	Trap 7	51	75	77
L31	8374.4	8375.1		Trap 7	51	76	86
L32	6910.9	6794.7	-Met, +CH <sub>2</sub>	Trap 14	48	60	63
L33	6413.6	6297.5	-Met, +CH <sub>2</sub>	Trap 11	55	67	69
L34	5194.2	5195.0		Trap 19			
L35	7353.8	7223.0	-Met	Trap 19	20	52	52
L36	4830.9	4830.1		Trap 17	34	31	34
Ribosomal Small Subunit Proteins							
S2	28701.8	28571.3	-Met	Trap 9	28	39	40
S3	28139.4	28011.9	-Met	Trap 14	49	60	66
S4	23287.6	23157.1	-Met	Trap 18	54	72	75
S5	21611.7	21496.6	-Met, +CH <sub>2</sub>	Trap 13	55	60	63
S6	14564.6	14434.9	-Met	Trap 8	68	72	84
S7	18001.6	17872.8	-Met	Trap 14	70	70	76
S8	14487.8	14357.3	-Met	Trap 8	60	71	78
S9	17186.7	17099.6	-Met, N-terminal acetylated	Trap 13	45	56	77
S10	11704.6	11705.3		Trap 10	34	60	61
S11	13774.7	13660.7	-Met, +CH <sub>2</sub>	Trap 11	33	43	45
S12	13825.4	13694.1	-Met	Trap 18	31	57	70
S13	13866.1	13733.0	-Met	Trap 16	66	68	84
S14	11433.5	11303.1	-Met	Trap 15	36	45	52
S15	10140.7	10011.0	-Met	Trap 14	48	58	59
S16	17604.7	17606.5		Trap 11	46	31	46
S17	8831.5	8701.5	-Met	Trap 11	65	48	81
S18	10113.9	10025.8	-Met, N-terminal acetylated	Trap 12	19	50	58
S19	10256.0	10125.6	-Met	Trap 12	77	65	88
S20	9928.6	9798.3	-Met	Trap 16	39	29	39
S21	10174.0	9062.4	Removal of residues 1-10	Trap 18	22	44	45

<sup>a</sup> "Theo(retical) mass" was calculated from the most recently deposited translated version of the *C. crescentus* genome available from The Institute for Genome Research using the in-house program PRODIGIES.<sup>25</sup> <sup>b</sup> "Location" corresponds to the trap where the protein has its highest intensity in deconvoluted whole protein spectra.


rations such as ours when cells are slowly cooled in the absence of puromycin, or by coprecipitation with rRNA during acid extraction.<sup>5,49-51</sup>

To confirm the proposed identities and post-translational modifications, several series of experiments based on enzymatic digests were performed. These experiments confirmed the identifications of all but the smallest proteins from the large ribosomal subunit (see below). Analysis of tryptic peptide samples also identified whole protein masses for L3, L21, and


S21. Complications associated with the identification of these proteins are discussed below.

The identification of ribosomal protein L16 illustrates the results obtained from the procedures described above. Figure 1 shows one example of a spectrum obtained by summing together 100 scans from a total ion chromatogram (TIC), along with the deconvoluted version of these data. A small contribution from ribosomal protein S20 also appears in the spectrum. A MALDI spectrum of the tryptic digest of a fraction from Trap






**Figure 1.** Whole protein mass spectra of ribosomal protein L16. (A) Raw spectrum with charge states for ribosomal protein L16 as indicated. Asterisks show the less intense +14 to +8 charge states of ribosomal protein S20. (B) Deconvoluted spectrum.




**Figure 2.** MALDI spectrum of the tryptic digest of a fraction collected from Trap 16. Peptides from proteins observed to elute in Trap 16 during whole protein experiments are assigned on the basis of mass and MS–MS fragmentation patterns. The mass scale of this figure has been truncated somewhat to improve the visibility of the assigned peptides; a peak at  $m/z = 2125.9$  (L16 residues 68–87) is not shown.

L16 is shown in Figure 2. This fraction contains peptides from other Trap 16 proteins (L4, S13, and S20), as well as proteins S7 and S14. Peptide assignments in Figure 2 are based on both peptide mass matches and fragmentation spectra. A representative example of an MS/MS spectrum is shown in Figure 3. Although the sequence coverage of L16 is 43%, no peptides containing the proposed modifications are observed.


Tryptic digest fractions from Trap 16 were also analyzed using capillary LC–MS/MS. In the case of ribosomal protein L16, coverage was slightly lower than that in the MALDI experiments, with peptides from essentially the same regions of the protein being observed. However, in these experiments, a singly charged pentapeptide with  $m/z$  of 589.6 Da was also observed to elute in a small peak at 13.5 min, as shown in Figure 4. This peptide’s mass corresponds to the N-terminal tryptic pentapeptide from L16 (MLSPK, 575.7 Da as a singly protonated peptide) with a mass increase of 14



**Figure 3.** TOF–TOF spectrum of an  $m/z = 1590.6$  peptide ion containing residues 102–115 of ribosomal protein L16 seen in Figure 2.



**Figure 4.** (A) Total ion chromatogram of a peptide digest from Trap 15, fraction 2. (B) Mass spectrum extracted from the TIC at the point indicated by an arrow (13.49 min), showing a peptide containing the methylated N-terminus of ribosomal protein L16.



**Figure 5.** The ESI-ion trap MS–MS spectrum for a peptide containing the modified amino terminus of ribosomal protein L16. With N-terminal methylation, the b<sub>4</sub> and y<sub>4</sub> ion mass-to-charge ratios differ by only 1 unit, and so the labels overlap.

Da. This would be consistent with the N-terminal methylation as performed by *E. coli*.<sup>52</sup> This peptide’s identification is supported by an MS–MS spectrum (Figure 5) containing a distinct series of y- and b-ions that are assignable assuming methylation. Tryptic peptide analysis experiments have pro-

**Table 2.** Observed Peptides That Confirm Proposed Post-Translational Modifications

	sequence	residues	mass	
N-terminal acetylation				
S9	*TDAQGFDALASLSSNPEAAAPEPK	2–26	2499.9	
S18	*TDTTAPEAGAPAAAAGGAR	2–20	1697.9	
Methylation of K				
L7/L12	GVRPDLGLK*EAK	80–91	1297.5	+3 ion, $m/z = 433.6$
L7/L12	GVRPDLGLK*	80–88	969.2	+2 ion, $m/z = 485.3$
N-terminal methylation				
L16	*MLSPK	1–5	589.8	+1 ion, $X_{\text{corr}} = 1.47$
Addition of 42 to K				
L11	TENVEK*GTPPLPTVITVYQDK*SFTFITK	46–72	3142.6	+3 ion, $m/z 1048.7$

vided no evidence for the identity or location of the second modification of L16.

**Post-Translational Modifications.** In several cases, we have directly observed the site of modification of *C. crescentus*'s ribosomal proteins. Ribosomal proteins L4, L13, L14, L29, L31, and S10 are proposed to be unmodified at their N-termini, and we have observed peptides containing unmodified N-termini. Methionine-truncated N-terminal peptides have been observed for ribosomal proteins L2, L5, L15, L19, L25, L30, S2, S6, S8, and S12.

Ribosomal proteins S9 and S18 are proposed to occur in their N-terminally acetylated forms. MALDI spectra contain masses attributed to both modified and unmodified N-terminal peptides. Deconvoluted whole protein spectra also show signals corresponding to unacetylated S9 (~10% of the intensity of the acetylated protein) and S18 (~5% of the intensity of the acetylated protein). A possible explanation for the presence of unmodified proteins is hydrolytic degradation of the N-terminal acetyl group during storage of the samples. It is also possible that this post-translational modification is not stoichiometric, or that the modification accumulates as a function of the age of the culture or its growth conditions. Table 1 summarizes other proposed modifications of *Caulobacter* ribosomal proteins. One notable absence is the  $\beta$ -thiomethylation of residue D89 in *C. crescentus* S12. This modification was first identified in *E. coli* S12 and has been observed in *T. thermophilus* S12.<sup>10,48</sup> This modification was undetected in whole protein data collected from *R. palustris*, although modified peptides were detected in tryptic digests.<sup>9</sup> No evidence of this modification has been detected in our tryptic digest experiments with *C. crescentus* ribosomal proteins, and it remains uncertain whether *C. crescentus* lacks the ability to perform this modification or simply does not modify its S12 homologue under the growth conditions we have studied.


**Special Cases and Notable Proteins. 1. Ribosomal Protein L3.** The calculated mass for L3 is 28 079.9 Da, or 27 948.7 Da without the N-terminal methionine. Neither of these masses was observed in the whole protein experiments. Nevertheless LC–ESI–MS experiments identified peptides from protein L3 in fractions collected from traps containing an intense, unidentified protein mass of 26 666.7 Da. Removal of residues 1–13 from the translated sequence results in a calculated mass of 26 666.4 Da, in good agreement with the unknown whole protein mass. Misassignment of the start codon seems to be a likely explanation for this sequence discrepancy, as discussed below. Finally, although the *E. coli* homologue of L3 (ExpASY Accession Number P60438) is known to be N-methylated at position Q150, the corresponding residue in *C. crescentus* L3 (ExpASY Accession Number Q9A8V3), Q156, does not appear to be modified.<sup>52,53</sup>

**2. Ribosomal Protein L11.** Tryptic digests of a fraction from Trap 7 that was associated with a protein mass of 15 509 Da contained multiple peptides attributed to L11. This protein mass is 253 Da higher than that predicted for L11, a modification equivalent to trimethylation or acetylation at six positions. Post-translational modifications of this type are found in L11 homologues from *E. coli* (three positions: N-terminus, K3, and K39),<sup>54</sup> *T. thermophilus* (four positions),<sup>55,56</sup> and *R. palustris* (four positions).<sup>9</sup> The positions of modification in the *E. coli* homologue are usually considered to be conserved. Tryptic digests of L11 include peptides generated by cleavage at K13, K114, K126, K133, and K138, allowing these residues to be eliminated from consideration as sites of modification. A triply charged ion of  $m/z$  1048.2 observed during analysis of Trap 7 was attributed to a peptide of mass 3142.6 Da containing residues 45–71. This match required two 42 Da modifications, suggesting that residues K50 and K64 are sites of modification (Table 2). Other candidates for which we have no data are K9, K80, K86, K90, K111, and K112.

To confirm that mass 15 509 Da should be associated with L11, pure protein was isolated using RPLC fractionation and subjected to C-terminal sequencing using carboxypeptidases Y and P. As shown in Figure 6, comparison of mass spectra from aliquots removed at different time points during digestion with a CPY/CPY mixture yielded a C-terminal sequence of (KI)-VEA, consistent with the C-terminal sequence of *C. crescentus* ribosomal protein L11 with no modifications at position K139.


We have identified peptides in an endoprotease Glu-C digest containing residues 50–63 (with a mass increase of 42 at position 50), residues 111–122 (no modifications), and residues 130–142 (no modifications). These results support the assignment of residue K50 as being a site of derivatization and rule out K111 and K112 as candidates.<sup>57</sup> Experiments are currently underway to better define the sites of modification of this protein and to determine whether the modifications are dependent on environmental or growth conditions.<sup>58</sup>

**3. Ribosomal Protein L7/L12.** Ribosomal proteins L7 and L12 are both products of the *rplL* gene (ORF CC0497 in the *C. crescentus* proteome). The amino acid sequence of these proteins is identical, and they differ only by the presence (L7) or absence (L12) of an N-terminal acetyl group.<sup>59,60</sup> *C. crescentus* does not appear to acetylate the N-terminus of its L7/L12 homologue as *E. coli* does under the growth conditions used for these experiments. Figure 7 shows the major form of *C. crescentus* L12 with a mass of 13 173 Da, corresponding to removal of the N-terminal methionine and addition of a methyl group. There is also a significant amount of a form of the protein with a mass of 13 186 Da, which indicates the addition of a second methyl group to the 13 173 Da form. Capillary LC–MS experiments have provided direct evidence for the site of one of the two proposed methylations. Figure 8 shows MS




**Figure 6.** C-Terminal sequence analysis of L11 using CPY/CPP. Deconvoluted mass spectra of L11; (A) digestion time = 0 min; (B) digestion time = 0.33 min; (C) digestion time = 1.5 min.

spectra of two tryptic peptides with overlapping sequence coverage (residues 80–88 and 80–91) whose masses are both consistent with a single methylation at K88. Supplemental Figure 1 in Supporting Information shows corresponding MS–MS spectra. The identity of the peptide containing residues 80–91 is corroborated by enhanced  $y_7$  and  $b_{10}$  ion formation due to the aspartyl residue at position 5 and the glutamyl residue at position 10 seen in Supplemental Figure 1A of Supporting Information. The spectrum of the overlapping peptide containing residues 80–88 in Supplemental Figure 1B of Supporting Information shows enhanced cleavage adjacent to the aspartyl residue. Fragments whose mass-to-charge ratios are consistent




**Figure 7.** (A) Deconvoluted mass spectrum from Trap 4 containing L7/L12; (B) expansion of the spectrum in panel A, showing the major, singly methylated form of L7/L12 (13 174.4 Da), the doubly methylated form (13 186.3 Da), and a small amount of unmethylated protein (13 159.4 Da).



**Figure 8.** ESI-ion trap mass spectra of modified peptides from L7/L12. (A) Triply protonated peptide ion containing residues 80–91. The 649.2 Th ion is the doubly protonated form of the peptide containing residues 80–91. The 613.3 Th ion is consistent with a doubly charged ion from which a glycine residue, and a further 16 Da have been lost. (B) Doubly protonated ion containing residues 80–88.

with the presence of the methyl substitution are indicated in the figure. A sequence alignment of the *E. coli* and *C. crescentus* proteins indicates that K88 in the *C. crescentus* sequence is homologous to K81 in the *E. coli* L7/L12 sequence, and as a result, this modification is likely to be temperature-dependent.<sup>61</sup>



**Figure 9.** (A) Sequence coverage map of N-terminally truncated S21. Underlined residues indicate the peptide masses observed. The shaded sequence is the absent N-terminal undecapeptide (see text for discussion). (B) MALDI spectrum of ribosomal protein S21 tryptic digest. (C) MALDI spectrum of ribosomal protein S21 Glu-C digest.

To date, we have not observed a peptide containing the proposed second site of modification of L7/L12.

**4. Ribosomal Protein L27.** An intense, recurring mass of 9111.2 Da was observed in fractions from Trap 12. This mass could not be associated with any ribosomal proteins by applying any of the expected post-translational modifications. The observation of tryptic peptides from L27 in fractions from this trap suggested that this unknown was a modified form of L27. The mass calculated after removal of the N-terminal methionine, 9239.5 Da, is 128 Da heavier than the observed 9111.2 Da. Because the predicted C-terminal sequence of L27 is AQPAAE, the 9111.2 Da unknown protein was tentatively identified as L27 with a single C-terminal residue truncation. Twenty-minute CPY/CPD digests of L27 were found to contain a whole protein species showing a clear loss of 71 Da from 9111 Da. This indicates that the C-terminal residue is alanine rather than glutamic acid, confirming the absence of the glutamate predicted by the proteomic sequence from the isolated form of the protein. Its absence may be due to exoproteolytic processing or more likely due to an error in the identification of the gene's stop codon (see below).

**5. Ribosomal Proteins S7 and L21.** A protein with a mass of 17 872.8 Da was observed to elute in Trap 15. This mass could be identified as either L21 plus a methyl group (17 871.6 Da) or S7 minus its N-terminal methionine (17 870.4 Da). Analysis of the tryptic digests using either LC-ESI-MS or MALDI MS showed that peptides from ribosomal protein S7 appeared in fractions collected from Traps 13–16, while peptides from Ribosomal Protein L21 appeared in fractions collected from Traps 13 and 14. The close match between the possible protein masses and the overlapping appearance of tryptic peptides made it difficult to conclusively identify the unknown mass.


To determine whether the 17 872.8 Da observed mass corresponded to S7 or L21, it was necessary to apply CPY/CPD C-terminal sequence tagging methodology. The predicted C-terminal sequence of S7 is SHYRW, and that of L21 is EEGEA. CPY/CPD analysis of the appropriate trap contents yielded C-terminal residues of R–W (Supplemental Figure 2 in Supporting Information). This indicated that the 17 872.8 Da protein mass corresponded to S7 and not L21. The C-terminal sequence analysis together with the extensive sequence cover-

age (70%) obtained from tryptic peptide analysis afforded definitive identification for ribosomal protein S7. Further inspection of protein mass spectra from Trap 13 revealed a low-intensity, irregularly occurring signal with a deconvoluted mass of 17 858.5 Da. This was assigned to unmodified L21 (Supplemental Figure 3 in Supporting Information).

**6. Ribosomal Protein S21.** Whole protein spectra did not contain peaks matching S21's predicted mass of 10 174.0 Da. Instead, an intense, recurring whole protein mass at 9062.4 Da was observed in Trap 18 (Supplemental Figure 4 in Supporting Information). Removal of residues 1–11 (MVGLSNGEIPL) from the translated sequence of S21 gave a theoretical mass of 9062.9. Tryptic digest experiments on the fractions collected from Trap 18 indicated the presence of peptides corresponding to S21 (44% sequence coverage in MALDI experiments).

To confirm the identification of S21, proteins collected from Trap 18 were subjected to CPY/CPD treatment. S21 has a C-terminal sequence of PMPKKPGR. CPY/CPD digestion of the protein resulted in the truncation of the arginine residue. Unfortunately, the slow hydrolysis through glycine and proline residues present in the adjacent positions, respectively, prevented further degradation of the protein, and no sequence information could be obtained.<sup>62–65</sup> For unambiguous identification, pure S21 was isolated using 1D-RPLC fractionation of the acetic acid/MgCl<sub>2</sub> supernatant and subjected to trypsin and Glu-C digestion. The peptides were analyzed by MALDI-TOF MS. The combined data from the two mass mapping experiments allowed us to identify the protein as S21 with matched peptides providing 82% sequence coverage (Figure 9A). As expected, there were no peptides corresponding to the first 11 amino acid residues, MVGLSNGEIPL (shaded in gray in Figure 9). Furthermore, the appearance of a peptide at mass 761.4 Da, matching an N-terminal sequence of VQIFVR (residues 12–17 of the predicted sequence), and a peptide at mass 1193.7 Da, matching the predicted C-terminal peptide (GLLPMPKKPGR), supported our hypothesis that the residues were absent from the N-terminus of the protein. The correlation of the data from whole protein analysis, peptide mass mapping, and C-terminal sequencing experiments unequivocally confirms that the 9062.6 Da mass occurring in Trap 18 represents the N-terminally truncated product of S21. Possible explanations for the trunca-





**Figure 10.** Deconvoluted mass spectra of ribosomal protein L34; (A) before CPY/CPP digestion; (B) following 10 s of CPY/CPP digestion.

tion of residues from the N-terminus are, as with L3, either proteolytic cleavage or an error in the reported genome sequence.

**7. Small Proteins from the Large Subunit.** The small proteins from the 50S subunit, L30–L36, were expected to present a challenge for identification because of the high fraction of K and R residues in their sequences (14% K + R in L32, up to 41% in L34, the average K + R percentage in proteins is 11%).<sup>66</sup> The use of C-terminal sequencing with CPY/CPP was invaluable in the identification of these proteins, especially ribosomal protein L34. The C-terminal sequence of L34 is VARRRAKRRLTA. As shown in Figure 10, digestion with CPY/CPP mixture resulted in sequential loss of up to 14 amino acid residues. The data obtained by CPY/CPP digestion were consistent with the translated sequence. This amounts to 32% sequence coverage by CPY/CPP analysis, and an unambiguous confirmation. Our identifications of ribosomal proteins L31, L32, L33, and L35 were also confirmed by determining their C-terminal sequences (Table 3).

## Discussion

**Whole Protein Masses.** The strategy for protein identification presented here is a pragmatic hybrid of “top down” and “bottom up” proteomic approaches.<sup>7,8,67</sup> Identifications based simply on protein masses are tentative, but because the ribosomal proteins comprise a distinct subcellular fraction of highly conserved proteins with a limited number of post-

**Table 3.** C-Terminal Sequence Analysis of Ribosomal Proteins from CPY/CPP Digest Experiments

protein	C-terminal sequence <sup>a</sup>
L11	(KI)VEA
L27	A
L31	RVS(RF)(NA)(KF)(AG)(FTG)KKA
L32	KQI(LTPK)ED
L33	E(FRE)(GK)IK
L34	VARRRA(KG)RKRL(TA)
L35	A(KI)IRT(YLP)YGL
S7	RW
S21	R

<sup>a</sup> The residues in parentheses indicate that the sequence order of the enclosed amino acids could not be determined.

translational modifications, these tentative identifications provide a solid foundation to complete the characterization of the proteome using bottom-up tactics involving peptide analysis. With this strategy, all but one of the ribosomal proteins of *C. crescentus* were identified. Several other studies in which protein identifications based on whole protein mass measurements were corroborated by sequence-based data have appeared recently. The ribosomal proteome of the  $\alpha$ -proteobacterium *R. palustris* has been characterized using parallel LC–ESI–FTICR MS of whole proteins and LC–ESI–IT MS–MS of tryptic digests.<sup>9</sup> The two-dimensional fractionation of the whole proteins prior to protein or peptide analysis allows the tryptic digest peptides obtained from a trap or trap fractions to be directly associated with a protein mass, increasing the confidence of an assignment. The collocation of proteins with peptides also allows smaller sets of LC–MS–MS data to be searched by SEQUEST or MASCOT for peptides containing post-translational modifications. The use of sequence homologies between *T. thermophilus* HB27 and HB8, and *T. thermophilus* IB-21 for which no genome sequence exists, to identify proteins observed in MALDI MS spectra, presents an alternative strategy to corroborate top-down measurements.<sup>10</sup> Confirming assigned identities by sequence homology between strains of the same species fulfills the same role as bottom-up identifications techniques, and streamlines the process of identification.

**Special Cases and Notable Proteins.** The three most dramatic discrepancies between the translated ribosomal proteome of *C. crescentus* and our observed protein masses are the absence of 13 and 11 residues at the N-termini of ribosomal proteins L3 and S21, and the truncation of the C-terminus of L27 by a single glutamate residue. Although proteolytic cleavage of ribosomal proteins has been observed in *E. coli*, the lack of extensive random proteolysis in our samples argues against damage during purification.<sup>38,68</sup> In each of these cases, the simplest explanation of the difference between the predicted and observed protein masses is an error in the interpretation of genome sequencing data. The first codon of L3’s gene (ORF CC1248) is the nonstandard start codon TTG. Thirty-six nucleotides downstream is an ATG codon. If the latter position were the correct translational start site, the predicted protein sequence would be 12 amino acids short, and N-terminal methionine aminopeptidase action would result in a protein with a mass (26 666.4 Da) within experimental error of the observed mass of L3 (26 666.7 Da). Examination of S21’s gene (ORF CC3297) shows a CTG codon 30 nucleotides downstream of the proposed TTG start codon. Assuming that the C residue at position 31 is in error and that it should be an A, the predicted protein sequence would be 10 amino acids shorter than the currently predicted sequence. Methionine removal

from the resulting protein would generate a protein with a predicted mass of 9062.9 Da, nearly identical to the observed value of 9062.9 Da. Only two of *C. crescentus*'s ribosomal proteins use TTG as a start codon: L3 is one of these proteins, and S21 is the other. TTG is the initiator codon for 3% of *E. coli*'s genes (and only one ribosomal protein gene, S20). Although there are no corresponding statistics for *C. crescentus*, these observations support the proposed errors in the interpretation of the genome sequencing data.<sup>69,70</sup> Ribosomal protein L27's gene (ORF CC0318) is terminated by the sequence GCC GAG TAA, coding for A-E-(Stop). Although TAA is the stop codon most frequently used by bacteria, assuming that the G in the first position of penultimate codon is in error, and that this codon should be TAG, results in a predicted sequence terminated by an alanine and a predicted mass of 9110.4 Da, comparable to the 9111.2 Da we have observed.<sup>71</sup>

**Chromatography.** An alternative means of summarizing data from a 20 trap experiment is presented in Supplemental Figure 5 of Supporting Information. Band broadening, especially in the ion-exchange dimension (horizontal), is a commonly observed phenomenon in chromatographic separations of ribosomal proteins. Despite the strongly denaturing conditions used in the ion-exchange dimension, some ribosomal proteins have enough ordered structure to interact heterogeneously with the chromatographic stationary phase or to interact reversibly with each other.<sup>72–74</sup> The most notable example of this behavior is seen with ribosomal protein L7/L12, which presents a broad horizontal smear, starting in Trap 4 with a secondary peak associated with the elution of ribosomal protein L10 in Trap 10. Similar interactions and coelution of proteins from *E. coli* ribosomes were observed by Diederich in a similar ion-exchange chromatography system.<sup>73</sup>

Band broadening in whole protein chromatography due to heterogeneous protein binding is a well-recognized problem, and there are three commonly applied tactics to minimize the effects: increasing flow rates, increasing temperature, and the addition of organic solvents to the mobile phase.<sup>75–78</sup> The modular nature of our system would allow the addition of a thermocouple-controlled heater to the ion-exchange column. Inclusion of organic solvent in the ion-exchange mobile phase also holds out the possibility of a modest increase in the capacity in this dimension and increased recovery of protein from the column.<sup>79</sup> These strategies will be explored in future work.

**Comparison of Different Peptide Mapping Procedures.** On the average, the LC-MS and MALDI tryptic peptide experiments each yields about 50% sequence coverage; the capillary chromatography-derived results have a broader range (80%–19%, average 47%) than the MALDI experiments (76%–23%, average 54%), but the results are more rapidly obtained, and experiments require less sample handling, no derivatization, and no sample clean up. The portions of each protein's sequence covered by each technique do not overlap exactly. Taken together, there is an average of 62% sequence coverage for each protein. The MALDI experiments, specifically those analyzed using PRODIGIES two-file comparisons, provide less ambiguous results.<sup>26</sup>

## Summary and Conclusions

A combined top-down/bottom-up approach allows fast identification of proteins in a mixture. A key step in this strategy is the separation of whole proteins on a two-dimensional LC system using strong cation exchange chromatography as the

first dimension and reversed-phase chromatography as the second dimension.<sup>28,80</sup> The second dimension of chromatography is developed from "trap" columns that retain proteins eluted from the ion-exchange dimension, concentrate them, and allow solvent exchange without the losses inherent in fraction collection and off-line sample handling. All of the commonly observed proteins of a eubacterial ribosomal proteome have been observed in samples obtained from *C. crescentus*. The extensive methylation (or acetylation) of L11 and the absence of  $\beta$ -thiomethylation of S12 are intriguing exceptions to the growing body of knowledge on ribosomal protein post-translational modifications. We are currently exploring both changes in the complement of post-translational modifications of *C. crescentus* ribosomal proteins as a function of growth conditions and the distribution of modifications to ribosomal proteins across a number of bacterial phyla.

**Acknowledgment.** We would like to thank Professor Yves Brun and Ellen Quardokus for the gift of *C. crescentus* CB15N cultures and information on this organism's growth and Dr. Ignatius J. Kass of Waters Corporation for AutoME 1.1. This research was supported by NIH Grant RR018942-01A2 and the Indiana Metacyte Initiative, and NSF grant CHE-0518234.

**Supporting Information Available:** Figure showing the fragmentation from the ions in Figure 8. Deconvoluted mass spectra of the C-terminal sequence analysis of S7 using CPY/CP. A deconvoluted mass spectrum from the Trap 13 TIC, showing a weak signal for L21. A deconvoluted mass spectrum showing the intense recurring mass corresponding to S21. Twenty serial reversed-phase trap chromatograms with protein identifications. Tables of IEC dimension gradient, regular RPLC gradient, longer RPLC gradient, carboxypeptidase-Y and -P digest analysis gradient, large-scale 1-D RPLC gradient for isolation of L11 and S21 for CPY/CP analysis, and RPLC gradient used for capillary LC/ESI-MS experiments. This material is available free of charge via the internet at <http://pubs.acs.org>.

## References

- Wittman, A. G. *Ann. Rev. Biochem.* **1982**, *51*, 155–183.
- Bremer, H.; Dennis, P. B. In *Escherichia coli and Salmonella: Cellular and Molecular Biology*, 2nd ed.; Neidhardt, F. C., et al. Eds.; American Society for Microbiology: Washington, DC, 1996; pp 1553–1564.
- Keener, J.; Nomura, M. In *Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology*, 2nd ed.; Neidhardt, F. C., et al. Eds.; American Society for Microbiology: Washington, DC, 1996; pp 1417–1431.
- Neidhardt, F. C.; Ingraham, J. L.; Schaecter, M. *Physiology of the Bacterial Cell: A Molecular Approach*; Sinauer Associates, Inc.: Sunderland, MA, 1990.
- Spedding, G. In *Ribosomes and Protein Synthesis: A Practical Approach*; Rickwood, D., Hames, B. D., Eds.; Oxford Press: New York, 1990; pp 1–29.
- O'Farrell, P. H. *J. Biol. Chem.* **1975**, *250* (10), 4007–4021.
- Link, A. J.; Eng, J.; Schietz, D. M.; Carmack, E.; Mize, G. J.; Morris, D. R.; Garvick, B. M.; Yates, J. R., III. *Nat. Biotechnol.* **1999**, *17*, 676–682.
- Washburn, M. P.; Wolters, D.; Yates, J. R., III. *Nat. Biotechnol.* **2001**, *19* (3), 242–247.
- Strader, M. B.; VerBerkmoes, N. C.; Tabb, D. L.; Connelly, H. M.; Barton, J. W.; Bruce, B. D.; Pelletier, D. A.; Davison, B. H.; Hettich, R. L.; Larimer, F. W.; Hurst, G. B. *J. Proteome Res.* **2004**, *3*, 965–978.
- Suh, M.-J.; Hamburg, D.-M.; Gregory, S. T.; Dahlberg, A. E.; Limbach, P. A. *Proteomics* **2005**, *5*, 4818–4831.
- Moore, P. B.; Steitz, T. A. *Annu. Rev. Biochem.* **2003**, *73*, 813–850.

- (12) Harms, J.; Schleunzen, F.; Zarovach, R.; Bashan, A.; Gat, S.; Agmon, I.; Bartels, H.; Fransechi, F.; Yonath, A. *Cell* **2001**, *107*, 679–688.
- (13) Wimberly, B. T.; Brodersen, D. E.; Clemmons, W. M., Jr.; Morgan-Warren, R. J.; Carter, A. P.; Vonnrhein, C.; Hartsch, T.; Ramakrishnan, V. *Nature* **2000**, *407*, 327–339.
- (14) Schleunzen, F.; Tocily, A.; Zaravach, R.; Harms, J.; Gluehmann, M.; Janell, D.; Bashan, A.; Bartels, H.; Agmon, I.; Fransechi, F.; Yonath, A. *Cell* **2000**, *102*, 615–623.
- (15) Yusupov, M. M.; Yusupova, G. Z.; Baucom, A.; Lieberman, K.; Earnest, T. N.; Cate, J. H. D.; Noller, H. F. *Science* **2001**, *292*, 883–896.
- (16) Schuwerth, B. S.; Borovinskaya, M. A.; Hau, C. W.; Zhang, W.; Vila-Sanjuzo, A.; Holton, J. M.; Cate, J. H. D. *Science* **2005**, *310*, 827–834.
- (17) Brodersen, D. E.; Nissen, P. *FEBS J.* **2005**, *272*, 2098–2108.
- (18) Wilson, D. N.; Nierhaus, K. H. *Crit. Rev. Biochem. Mol. Biol.* **2005**, *40*, 243–267.
- (19) Woese, C. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 6854–6859.
- (20) Woese, C. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 8742–8747.
- (21) Walsh, C. *Antibiotics: Actions, Origins, Resistance*; ASM Press: Washington, DC, 2003.
- (22) Slee, A. M.; Wuonola, M. A.; McRipley, R. J.; Zajac, I.; Zawada, M. J.; Bartholomew, P. T.; Gregory, W. A.; Forbes, M. *Antimicrob. Agents Chemother.* **1987**, *31*, 1791–1797.
- (23) Livermore, D. J. *Antimicrob. Chemother.* **2003**, *51* (Suppl. S2), ii9–ii16.
- (24) Abbot, A. *Nature* **2005**, *436*, 758.
- (25) Karty, J. A.; Ireland, M. M. E.; Brun, Y. V.; Reilly, J. P. *J. Proteome Res.* **2002**, *1*, 325–335.
- (26) Karty, J. A.; Ireland, M. M. E.; Brun, Y. V.; Reilly, J. P. *J. Chromatogr., B* **2002**, *782*, 363–383.
- (27) Ireland, M. M. E.; Karty, J. A.; Quardokus, E. M.; Reilly, J. P.; Brun, Y. V. *Mol. Microbiol.* **2002**, *45*, 1029–1041.
- (28) Karty, J. A.; Running, W. E.; Reilly, J. P. *J. Chromatogr., B* **2006**, published online Oct 23, <http://dx.doi.org/10.1016/j.jochromb.2006.09.043>.
- (29) Emelyanov, V. V. *FEBS Lett.* **2001**, *501*, 11–18.
- (30) Thiede, B.; Wittmann-Liebold, B.; Bienert, M.; Krause, E. *FEBS Lett.* **1995**, *357*, 65–69.
- (31) Bonetto, V.; Bergman, A.-C.; Joernvall, H.; Sillard, R. *Anal. Chem.* **1997**, *69*, 1315–1319.
- (32) Rosnack, K. J.; Stroth, J. G. *Rapid Commun. Mass Spectrom.* **1992**, *6*, 637–640.
- (33) Nguyen, D. N.; Becker, G. W.; Rigglin, R. M. *J. Chromatogr., A* **1995**, *705*, 21–45.
- (34) Patterson, D. H.; Tarr, G. E.; Regnier, F. E.; Martin, S. A. *Anal. Chem.* **1995**, *67*, 3971–3978.
- (35) Nierman, W. C.; Feldblyum, T. V.; Laub, M. T.; et al. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 4136–4141.
- (36) Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.-C.; Estreicher, A.; Gasteiger, E.; Martin, M. J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M. *Nucleic Acids Res.* **2003**, *31*, 365–370.
- (37) Tatusova, T. A.; Madden, T. L. *FEMS Microbiol. Lett.* **1999**, *174*, 247–250.
- (38) Arnold, R. J.; Reilly, J. P. *Anal. Biochem.* **1999**, *269*, 105–112.
- (39) Read, S. M.; Northcoate, D. H. *Anal. Biochem.* **1981**, *116*, 53–64.
- (40) Hardy, S. J. S.; Kurland, C. G.; Voynow, P.; More, G. *Biochemistry* **1969**, *8*, 2897–2905.
- (41) Eng, J. K.; McCormack, A. L.; Yates, J. R., III. *J. Am. Soc. Mass Spectrom.* **1994**, *5*, 976–989.
- (42) Yates, J. R., III; Eng, J. K.; McCormack, A. L.; Schieltz, D. *Anal. Chem.* **1995**, *67*, 1426–1436.
- (43) Beardsley, R. L.; Reilly, J. P. *Anal. Chem.* **2002**, *74*, 1884–1890.
- (44) Pappen, D. J. C.; Hoyrup, P.; Bleasby, A. J. *Curr. Biol.* **1993**, *3*, 327–332.
- (45) Arnold, R. J.; Karty, J. A.; Ellington, A. D.; Reilly, J. P. *Anal. Chem.* **1999**, *71*, 1990–1996.
- (46) Hirel, P.-H.; Schmitter, J.-M.; Dessen, P.; Fayat, G.; Blanquet, S. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 8247–8251.
- (47) Dalbøge, H.; Bayne, S.; Pedersen, J. *FEBS Lett.* **1990**, *266*, 1–3.
- (48) Kowalak, J. A.; Walsh, K. A. *Protein Sci.* **1996**, *5*, 1625–1632.
- (49) Subramanian, A. R. *Prog. Nucleic Acids Res. Mol. Biol.* **1983**, *28*, 101–142.
- (50) Kalapos, M. P.; Paulus, H.; Sarkar, N. *Biochimie* **1997**, *79*, 493–502.
- (51) Deusser, E.; Weber, H. J.; Subramanian, A. R. *J. Mol. Biol.* **1974**, *84*, 249–256.
- (52) Alix, J.-H. *Adv. Exp. Med. Biol.* **1988**, *231*, 371–385.
- (53) Muranova, T. A.; Muranov, A. V.; Markova, L. F.; Ovchinnikov, Y. A. *FEBS Lett.* **1978**, *96*, 301–305.
- (54) Dognin, M. J.; Wittman-Liebold, B. *Eur. J. Biochem.* **1980**, *112*, 131–151.
- (55) Triantafyllidou, D.; Simitopoulou, M.; Franceschi, F.; Choli-Papadopoulou, T. *J. Protein Chem.* **1999**, *18*, 215–223.
- (56) Cameron, D. M.; Gregory, S. T.; Thompson, J.; Suh, M. J.; Limbach, P. A.; Dahlberg, A. E. *J. Bacteriol.* **2004**, *186*, 5819–5825.
- (57) Beardsley, R. L.; Running, W. E.; Reilly, J. P. *J. Proteome Res.* **2006**, *5*, 2935–2946.
- (58) Running, W. E.; Reilly, J. P. *Proceedings of the 54th ASMS Conference on Mass Spectrometry and Allied Topics*, Seattle WA, May 28–June 1, 2006; Poster Abstract TP32–585.
- (59) Wahl, M. C.; Moller, W. *Curr. Protein Pept. Sci.* **2002**, *3*, 93–106.
- (60) Deusser, E. *Mol. Gen. Genet.* **1972**, *119*, 249–258.
- (61) Chang, F. N. *J. Bacteriol.* **1978**, *135*, 1165–1166.
- (62) Lu, S. H.; Klein, M. L.; Lai, P.-H. *J. Chromatogr.* **1988**, *447*, 351–364.
- (63) Yokoyama, S.; Oobayashi, A.; Tanabe, O.; Ichishima, E. *Biochim. Biophys. Acta* **1975**, *397*, 443–448.
- (64) Hayashi, R.; Bai, Y.; Tadao, H. *J. Biochem.* **1975**, *77*, 69–79.
- (65) Hayashi, R. *Methods Enzymol.* **1976**, *45*, 568–587.
- (66) Creighton, T. E. *Proteins: Structures and Molecular Properties*, 2nd ed.; W. H. Freeman: New York, 1993.
- (67) Kelleher, N. L.; Lin, H. Y.; Valaskovic, G. A.; Aaserud, D. J.; Fridriksson, E. K.; McLafferty, F. W. *J. Am. Chem. Soc.* **1999**, *121*, 806–812.
- (68) Wada, A. *Genes Cells* **1998**, *3*, 203–208.
- (69) Blattner, F. R.; Plunkett, G., III; Bloch, C. A.; et al. *Science* **1997**, *277*, 1453–1462.
- (70) Stenstrom, C. M.; Holmgren, E.; Isaksson, L. A. *Gene* **2001**, *273*, 259–265.
- (71) Sharp, P. M.; Bulmer, P. *Gene* **1988**, *63*, 141–145.
- (72) Kamp, R. M.; Bosserhoff, A.; Kamp, D.; Wittman-Liebold, B. *J. Chromatogr.* **1984**, *317*, 181–192.
- (73) Diedrich, G.; Burkhardt, N.; Nierhaus, K. H. *Protein Expression Purif.* **1997**, *10*, 42–50.
- (74) Dijk, J.; Littlechild, J. *Methods Enzymol.* **1979**, *59*, 481–502.
- (75) Parente, E. S.; Wetlaufer, D. B. *J. Chromatogr.* **1984**, *314*, 337–347.
- (76) Liu, H.; Berger, S. J.; Chakraborty, A. B.; Plumb, R. S.; Cohen, S. A. *J. Chromatogr., B* **2002**, *782*, 267–289.
- (77) Cohen, S. A.; Benedek, K.; Tapuhi, Y.; Ford, J. C.; Karger, B. L. *Anal. Biochem.* **1985**, *144*, 275–284.
- (78) Fang, F.; Aguilar, M.-I.; Hearn, M. T. W. *J. Chromatogr., A* **1996**, *729*, 67–79.
- (79) Pantazak, A.; Baron, M.-H.; Revault, M.; Vidal-Medjar, C. *J. Colloid Interface Sci.* **1998**, *207*, 324–331.
- (80) Chong, B. E.; Yan, F.; Lubman, D. M.; Miller, F. R. *Rapid Commun. Mass Spectrom.* **2001**, *15*, 291–296.

PR060306Q